Join Brian Lanman of Amgen as he outlines the strategies used to overcome these challenges, the screening approaches employed to identify starting points for these efforts, and the optimization ...

While Regeneron may have lost its latest bid to block the launch of Amgen’s Eylea biosimilar Pavblu, the New York-based pharma isn’t throwing in the towel just yet. At the same time ...

Sometimes interesting stories from the ASCO conference are the phase I data that generates hope for the future. One such story at ASCO 2019 was the data on Amgen’s KRAS inhibitor AMG 510.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Amgen (NASDAQ: AMGN) stock is up 13% this year but has struggled to break out above a tight trading range in recent months.

Amgen (Thousand Oaks, CA) has won its US district court patent battle against Transkaryotic Therapies (TKT; Cambridge, MA) and Aventis Pharmaceuticals (Bridgewater, NJ) over its multi-billion ...

Are you a print subscriber? Activate your account. By Mikey Garcia - 41 min 54 sec ago By Adrianne Pasquarelli - 1 hour 4 min ago By Ad Age and Creativity Staff - 1 hour 13 min ago By Brandon ...

Salveen Richter has given his Buy rating due to a combination of factors that highlight Amgen’s potential growth prospects. A critical focus is on the upcoming Phase 2 obesity data for MariTide ...

Amgen Inc.'s Q3 earnings — due 30th October -are unlikely to be a major upside catalyst due to tricky comparisons, increased R&D spending, and transitional phase challenges. Key patents expiring ...

The latest trading session saw Amgen (AMGN) ending at $325.09, denoting a +0.14% adjustment from its last day's close. The stock's change was more than the S&P 500's daily loss of 0.76%.

Wall Street expects a year-over-year increase in earnings on higher revenues when Amgen (AMGN) reports results for the quarter ended September 2024. While this widely-known consensus outlook is ...

Amgen is posting strong growth across its diversified-medicines portfolio. A new weight-loss drug candidate could be a game-changer for the company. Trading at 17 times earnings, the stock offers ...